Zevra Therapeutics, Inc. (NASDAQ:KMPH) Short Interest Down 5.5% in February
Zevra Therapeutics, Inc. (NASDAQ:KMPH) Short Interest Down 5.5% in February
Zevra Therapeutics, Inc. (NASDAQ:KMPH – Get Rating) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,370,000 shares, a decline of 5.5% from the January 31st total of 1,450,000 shares. Based on an average daily trading volume, of 210,400 shares, the short-interest ratio is currently 6.5 days. Approximately 4.4% of the company's stock are sold short.
澤弗拉治療, 公司. (NASDAQ: KMPH — 獲取評級) 是在短期利益大幅下降的收件人在二月份.截至 2 月 15 日，短期利息共計 1,370,000 股，較一月三十一日共有 1,450,000 股股份下降 5.5%。根據每日平均交易量為 210,400 股，短息比率目前為 6.5 天。約 4.4% 的公司股票賣空。
Insider Activity
內幕活動
In other news, CEO Richard W. Pascoe purchased 9,500 shares of the company's stock in a transaction that occurred on Friday, January 13th. The shares were bought at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the purchase, the chief executive officer now directly owns 19,973 shares in the company, valued at approximately $108,653.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.10% of the company's stock.
在其他消息中，首席執行官理查德 ·W· 帕斯科在 1 月 13 日（星期五）發生的交易中購買了該公司股票的 9,500 股。這些股份以每股 5.44 美元的平均價格買入，總交易額為 51,680.00 美元。收購後，首席執行官現直接擁有該公司 19,973 股股份，價值約為 108,653.12 美元。該交易在與證券交易委員會的法律文件中披露，該交易可通過以下方式獲得 這個鏈接。公司內部人士擁有公司股票的 1.10％。
Institutional Investors Weigh In On Zevra Therapeutics
機構投資者權衡 Zevra 治療
A number of large investors have recently made changes to their positions in KMPH. UBS Group AG bought a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $26,000. Verition Fund Management LLC bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $46,000. Invesco Ltd. purchased a new position in shares of Zevra Therapeutics during the 1st quarter worth $51,000. Kingsview Wealth Management LLC purchased a new stake in shares of Zevra Therapeutics in the 2nd quarter worth $54,000. Finally, HRT Financial LP bought a new position in Zevra Therapeutics in the 4th quarter worth $66,000. 19.39% of the stock is currently owned by institutional investors.
一些大型投資者最近更改了他們在 KMPH 中的倉位。瑞銀集團股份公司在第二季度購買了 Zevra 治療學股份的新頭寸，價值約為 26,000 美元。驗證基金管理有限責任公司在 Zevra 治療學的第四季度收購了一個新的位置，價值約為 46,000 美元。景順有限公司在第一季度購買了 Zevra 治療的新股份，價值 51,000 美元。金景財富管理有限責任公司在第二季度購買了 Zevra 治療藥物股份的新股份，價值 54,000 美元。最後，HRT 金融有限公司在第四季度買入了 Zevra 治療學的新頭寸，價值 66,000 美元。目前，該股票的 19.39％ 由機構投資者擁有。
Zevra Therapeutics Stock Performance
Zevra 治療學股票表現
Shares of KMPH opened at $5.81 on Wednesday. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.14. Zevra Therapeutics has a one year low of $4.00 and a one year high of $6.92. The business has a fifty day moving average of $5.34 and a 200 day moving average of $5.37.
KMPH 股票在周三以 5.81 美元開盤。該公司的快速比率為 10.10，流動比率為 10.10，債務與權益比率為 0.14。澤弗拉治療學的一年低點為 4.00 美元，一年高點為 6.92 美元。該業務有五十天移動平均線為 5.34 美元和 200 日移動平均線為 5.37 美元。
Wall Street Analyst Weigh In
華爾街分析師稱重
A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Zevra Therapeutics in a research note on Thursday, November 17th. They issued an "overweight" rating and a $20.00 price target on the stock. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $20.00 to $19.00 in a research note on Thursday, November 10th. Finally, StockNews.com raised Zevra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.25.
一些股票分析師最近發布了有關該股票的報告。坎托·菲茨杰拉德承擔了 Zevra 治療的股份覆蓋率在研究筆記上週四, 11 月 17 日.他們發布了「超重」評級和 20.00 美元的股票價格目標。坎雅克誠集團在 11 月 10 日（星期四）的一份研究報告中，將 Zevra 治療藥物股票的價格目標從 20.00 美元降至 19.00 美元。最後，Stocknews.com 在 11 月 19 日星期六的一份研究報告中將 Zevra 治療從「賣出」評級提高到「持有」評級。一位投資分析師將該股票評級為持有評級，其中四名則對該公司股票給予買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為「適度買入」，平均目標價為 17.25 美元。
About Zevra Therapeutics
關於澤弗拉治療
(Get Rating)
(取得評分)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
KemPharm, Inc 是一家臨床階段的專業製藥公司，從事專有前藥的發現和開發。它通過其稱為配體活化療法的平台技術，專注於治療嚴重的醫療條件，例如注意力缺陷多動障礙，疼痛和其他中樞神經系統疾病。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets "Powelled": S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023's Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
- 獲取有關澤弗拉治療學（KMPH）的研究報告的免費副本
- 雷達下 Azul SA 在強勁的旅行需求下飛行
- 市場變得「波動」：標普 500 證實阻力
- 利維安暴跌，但這是 2023 年最大的購買機會嗎？
- Ulta 內部人士保持緊張：賣方網站購買
- 潛在收益已將 Ambrx 生物製藥評為適度買入
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Zevra 治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Zevra 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。